AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor dapagliflozin has been indicated for the treatment of type 2 diabetes since 2012.  AstraZeneca Plc's (NASDAQ: AZN) dapagliflozin 5mg (Forxiga/Farxiga) was authorized in 2019 as an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) of 27 kg per m2.

AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK

With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.

AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug

People with compromised immune systems aren't as protected by the coronavirus vaccines.

FDA authorizes AstraZeneca COVID prevention drug for immunocompromised people

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer

The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines. The antibody cocktail, Evusheld (AZD7442), is only authorized for adults and adolescents who are not currently infected with the novel coronavirus and have not recently been exposed to an infected individual.

AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised

U.S.-listed shares of AstraZeneca AZN, +0.68% were up 0.3% in after-hours trading on Wednesday after the Food and Drug Administration authorized the company's COVID-19 monoclonal antibodies for pre-exposure prophylaxis in individuals who are immunocompromised or have a history of severe adverse reactions to a COVID-19 vaccine. In both instances, the individuals, who must be at least 12 years old, may not be able to gain protective antibodies through COVID-19 vaccination.

FDA authorizes AstraZeneca's monoclonal antibodies for some who can't get vaccinated or are immunocompromised

Ionis Pharma

Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.

Ionis (IONS) Collaborates With AstraZeneca for Eplontersen

Moderna

Pfizer

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) shots followed by Moderna Inc's (NASDAQ: MRNA) nine weeks later. AstraZeneca-Oxford vaccine followed by a Moderna or Novavax Inc (NASDAQ: NVAX) shot showed higher antibodies and T-cell responses versus two doses of AstraZeneca-Oxford.

Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer

Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and commercialize eplontersen, Ionis' antisense medicine for transthyretin amyloidosis (ATTR). ATTR is a slowly progressive condition characterized by the buildup of abnormal protein deposits called amyloid (amyloidosis) in the body's organs and tissues.

Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder

Alexion Pharma

AstraZeneca PLC (LSE:AZN)'s acquisition of Alexion Pharmaceuticals (NASDAQ:ALXN) Inc was the highlight of a third-quarter that saw UK companies splash out £32.8bn on acquisitions. Figures from the Office for National Statistics (ONS) show that while the three months to the end of September saw a decline in merger & acquisition (M&A) deals to 136 a month from 164 in the preceding quarter, UK companies flexed their muscle overseas a bit more, with foreign businesses acquired valued at £32.8bn, well up from £8.2bn in the preceding quarter.

AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions

AstraZeneca PLC (LSE:AZN) has agreed a licensing deal worth potentially worth almost as much as the market capitalisation of the Californian biotech it is teaming up with. The transactions could see AZ hand over as much as US$3.585bn to Ionis Pharmaceuticals (NASDAQ:IONS) Inc (current valuation US$3.88bn).

AstraZeneca agrees licensing deal with California biotech worth up to US$3.5bn

AbbVie

Regeneron Pharmaceuticals

Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?

5 Biotech Stocks To Watch In The Stock Market Today

The pharmaceutical is a high-quality dividend stock that offers investors tremendous growth at a reasonable price.

Here's Why AstraZeneca Stock Could Help Make You Rich

Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) December 7-10, 2021. Fourteen AstraZeneca medicines and potential new medicines from the pipeline will be featured across 33 abstracts showcasing the Company's leadership across different types and stages of breast cancer, including three oral presentations. Breast cancer is now the mo

AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by Advent International and Singapore wealth fund GIC. Advent and Singapore's sovereign wealth fund said they were withdrawing their bid for SOBI.

AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report

Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to prevent the rare side effect. The preclinical research conducted with AstraZeneca found that the interaction between the vaccine and a protein known as platelet factor 4 could be behind the cases of thrombosis with thrombocytopenia syndrome.

Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots

Scientists claim to have discovered a "potential mechanism" that triggers blood clots in some people who receive the Oxford-AstraZeneca Covid vaccine.

Scientists identify reaction that may cause rare blood clots after AstraZeneca Covid vaccine

Merck

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

Amgen

Bristol-Myers

Horizon Pharma

Novartis

Vertex Pharmaceuticals

Viatris

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.

7 Drug Stocks to Buy Now While They're Still on Sale

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer

DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer. The application for Lynparza covers the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting

The University of Oxford said it can rapidly update the COVID-19 vaccine if it needs to be modified to cope with the Omicron variant of coronavirus. The university, which pioneered the vaccine developed by AstraZeneca PLC (LSE:AZN), said it has all the “necessary tools and processes” in place for updating the jab.

Oxford University says it can quickly update AstraZeneca's COVID-19 vaccine

Merck & Co. Inc. MRK, -5.39% and AstraZeneca PLC AZN, -1.86% said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S. Food and Drug Administration. Lynparza's sNDA is for the adjuvant treatment of patients with BRCA-mutated, human epidermal growth factor receptor 2-negative high-risk early breast cancer who have already been treated with chemotherapy.

News for AstraZeneca Stock (AZN)